Madison Investment Holdings Inc. cut its position in Amgen Inc. (NASDAQ:AMGN) by 10.3% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 130,544 shares of the medical research company’s stock after selling 15,000 shares during the period. Madison Investment Holdings Inc.’s holdings in Amgen were worth $21,418,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of AMGN. TrimTabs Asset Management LLC grew its position in shares of Amgen by 88.9% in the 1st quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock valued at $100,000 after buying an additional 288 shares during the last quarter. Alpha Omega Wealth Management LLC grew its position in shares of Amgen by 19.0% in the 1st quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock valued at $103,000 after buying an additional 100 shares during the last quarter. Jackson Grant Investment Advisers Inc. grew its position in shares of Amgen by 0.6% in the 1st quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock valued at $104,000 after buying an additional 4 shares during the last quarter. Nelson Roberts Investment Advisors LLC purchased a new position in shares of Amgen in the 1st quarter valued at $121,000. Finally, Signature Estate & Investment Advisors LLC grew its position in shares of Amgen by 13.6% in the 1st quarter. Signature Estate & Investment Advisors LLC now owns 794 shares of the medical research company’s stock valued at $130,000 after buying an additional 95 shares during the last quarter. 78.13% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This report was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://www.thecerbatgem.com/2017/09/06/amgen-inc-amgn-holdings-lowered-by-madison-investment-holdings-inc.html.

Shares of Amgen Inc. (NASDAQ AMGN) traded up 0.53% during mid-day trading on Wednesday, hitting $177.67. 649,443 shares of the company traded hands. Amgen Inc. has a 52-week low of $133.64 and a 52-week high of $184.21. The firm has a market cap of $129.64 billion, a price-to-earnings ratio of 16.18 and a beta of 1.35. The firm has a 50-day moving average price of $173.66 and a 200 day moving average price of $168.55.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, topping the consensus estimate of $3.11 by $0.16. The business had revenue of $5.81 billion during the quarter, compared to the consensus estimate of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The company’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.84 earnings per share. Equities research analysts anticipate that Amgen Inc. will post $12.57 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Thursday, August 17th will be issued a $1.15 dividend. This represents a $4.60 annualized dividend and a yield of 2.60%. The ex-dividend date of this dividend is Tuesday, August 15th. Amgen’s payout ratio is currently 41.93%.

A number of research firms recently commented on AMGN. Cann reaffirmed a “buy” rating and issued a $203.00 target price (up from $189.00) on shares of Amgen in a research report on Wednesday, July 26th. BMO Capital Markets downgraded shares of Amgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, July 26th. Deutsche Bank AG reaffirmed a “hold” rating and issued a $174.00 target price (up from $172.00) on shares of Amgen in a research report on Wednesday, July 26th. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and issued a $203.00 target price (up from $189.00) on shares of Amgen in a research report on Wednesday, July 26th. Finally, Cowen and Company reaffirmed an “outperform” rating and issued a $209.00 target price on shares of Amgen in a research report on Saturday, July 22nd. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company. Amgen presently has a consensus rating of “Buy” and an average target price of $186.04.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.